Publications

Detailed Information

Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers

DC Field Value Language
dc.contributor.authorSong, Chang Hoon-
dc.contributor.authorPark, So Yeon-
dc.contributor.authorEom, Keun-Yong-
dc.contributor.authorKim, Jee Hyun-
dc.contributor.authorKim, Jae Sung-
dc.contributor.authorKim, In Ah-
dc.contributor.authorKim, Sung-Won-
dc.date.accessioned2012-06-01T07:53:18Z-
dc.date.available2012-06-01T07:53:18Z-
dc.date.issued2010-
dc.identifier.citationBREAST CANCER RESEARCH; Vol.12 2; -ko_KR
dc.identifier.issn1465-5411-
dc.identifier.urihttps://hdl.handle.net/10371/76722-
dc.description.abstractIntroduction: Evaluating the expression of signaling molecule proteins from the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3-kinase (PI3K) pathway in invasive breast cancers may identify prognostic marker(s) associated with early relapse. Methods: Immunohistochemical analyses of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), PI3K-p110a, phospho-AKT, phospho-p70S6 kinase, phospho-S6 ribosomal protein, phospho-RAF, phospho-p44/42 MAPK, and heat-shock protein 90 (HSP90) were performed on tumor samples from 212 patients with invasive breast cancer. Statistically significant relations between protein expression, clinicopathologic factors, and relapse-free survival (RFS) were analyzed. Results: Expression of HSP90 was associated with 5-year RFS, as well as T stage, N stage, histologic grade, estrogen receptor (ER) expression, human epidermal growth factor receptor 2 (HER2) expression, and the Ki-67 proliferation index. On multivariate analysis, coexpression of HSP90 and PI3K-p110a or expression of HSP90 along with PTEN loss demonstrated significantly worse RFS. In subgroup analyses, both exhibited strong prognostic significance in HER2-positive cases, but not in HER2-negative cases. Conclusions: The coexpression of HSP90 with PI3K-p110a or expression of HSP90 along with PTEN loss has a potential as a molecular prognostic marker to predict early relapse in patients with invasive breast cancers.ko_KR
dc.language.isoenko_KR
dc.publisherBIOMED CENTRAL LTDko_KR
dc.titlePotential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancersko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor송창훈-
dc.contributor.AlternativeAuthor박소연-
dc.contributor.AlternativeAuthor엄근용-
dc.contributor.AlternativeAuthor김지현-
dc.contributor.AlternativeAuthor김성원-
dc.contributor.AlternativeAuthor김재성-
dc.contributor.AlternativeAuthor김인아-
dc.identifier.doi10.1186/bcr2557-
dc.citation.journaltitleBREAST CANCER RESEARCH-
dc.description.citedreferenceNo M, 2009, CANCER BIOL THER, V8, P2351-
dc.description.citedreferenceEralp Y, 2008, ANN ONCOL, V19, P669, DOI 10.1093/annonc/mdm522-
dc.description.citedreferenceLai YL, 2008, ANN SURG ONCOL, V15, P1064, DOI 10.1245/s10434-007-9751-7-
dc.description.citedreferenceHyun CL, 2008, J CLIN PATHOL, V61, P317, DOI 10.1136/jcp.2007.050336-
dc.description.citedreferenceWirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124-
dc.description.citedreferenceMarty B, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2204-
dc.description.citedreferenceBerns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030-
dc.description.citedreferenceLee JY, 2007, SCIENCE, V317, P206, DOI 10.1126/science.1146073-
dc.description.citedreferenceSaal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104-
dc.description.citedreferencePick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511-
dc.description.citedreferencePowers MV, 2006, ENDOCR-RELAT CANCER, V13, pS125, DOI 10.1677/erc.1.01324-
dc.description.citedreferenceFan C, 2006, NEW ENGL J MED, V355, P560-
dc.description.citedreferenceEngelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879-
dc.description.citedreferenceCully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819-
dc.description.citedreferenceBose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525-
dc.description.citedreferenceKim IA, 2005, CANCER RES, V65, P7902, DOI 10.1158/0008-5472.CAN-05-0513-
dc.description.citedreferenceGrann VR, 2005, CANCER, V103, P2241, DOI 10.1102/cncr.21030-
dc.description.citedreferenceLevine DA, 2005, CLIN CANCER RES, V11, P2875-
dc.description.citedreferenceSchlessinger J, 2004, SCIENCE, V306, P1506-
dc.description.citedreferenceSchmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002-
dc.description.citedreferenceHAGE JA, 2004, BRIT J CANCER, V90, P1543-
dc.description.citedreferenceKamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913-
dc.description.citedreferenceTrihia H, 2003, CANCER, V97, P1321-
dc.description.citedreferenceNECKERS L, 2003, CURR OPIN ONCOL, V15, P419-
dc.description.citedreferencePerez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj/bjc/6600126-
dc.description.citedreferenceMunster PN, 2001, CLIN CANCER RES, V7, P2228-
dc.description.citedreferenceSlamon DJ, 2001, NEW ENGL J MED, V344, P783-
dc.description.citedreferenceYARDEN Y, 2001, NAT REV MOL CELL BIO, V2, P137-
dc.description.citedreferenceHanahan D, 2000, CELL, V100, P57-
dc.description.citedreferenceHUANG MC, 1999, SEMIN ONCOL, V26, P51-
dc.description.citedreferenceRAVDIN PM, 1992, J CLIN ONCOL, V10, P1284-
dc.description.citedreferenceHENSON DE, 1991, CANCER, V68, P2142-
dc.description.citedreferenceELSTON CW, 1991, HISTOPATHOLOGY, V19, P403-
dc.description.citedreferencePAIK S, 1990, J CLIN ONCOL, V8, P103-
dc.description.citedreferenceSLAMON DJ, 1987, SCIENCE, V235, P177-
dc.description.citedreferenceCLARK GM, 1983, PROG CLIN BIOL RES, V132, P183-
dc.description.tc2-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share